BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
- Conditions
- Juvenile Psoriatic Arthritis
- Interventions
- Other: Placebo
- First Posted Date
- 2025-03-11
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 60
- Registration Number
- NCT06869551
- Locations
- 🇧🇷
Local Institution - 0032, Cuiabá, Mato Grosso, Brazil
🇪🇸Hospital Universitari i Politecnic La Fe, València, Spain
🇹🇷Local Institution - 0043, Istanbul- Fatih, İstanbul, Turkey
A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion
- First Posted Date
- 2025-03-04
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 130
- Registration Number
- NCT06855771
- Locations
- 🇺🇸
Local Institution - 0088, Anchorage, Alaska, United States
🇺🇸Local Institution - 0099, Boise, Idaho, United States
🇺🇸Local Institution - 0090, Boston, Massachusetts, United States
A Study to Evaluate Luspatercept Treatment Patterns and Outcomes in Erythropoiesis-Stimulating Agents-Naïve Patients With Lower-Risk Myelodysplastic Syndromes in the United States
- Conditions
- Myelodysplastic Syndromes
- Interventions
- Drug: Erythropoiesis-stimulating agents
- First Posted Date
- 2025-02-28
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 400
- Registration Number
- NCT06851065
- Locations
- 🇺🇸
RTI Health Solutions, Raleigh, North Carolina, United States
Safety, Tolerability, and Pharmacokinetics of KarXT and Dual-burst Release of Xanomeline With Immediate-release Trospium Chloride in Adolescents With Psychiatric Disorders
- First Posted Date
- 2025-02-28
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 36
- Registration Number
- NCT06853171
- Locations
- 🇺🇸
Pillar Clinical Research- Little Rock, Little Rock, Arkansas, United States
🇺🇸NRC Research Institute, Orange, California, United States
🇺🇸CenExel iResearch, LLC, Decatur, Georgia, United States
A Study to Evaluate the Bioequivalence Between Immediate Release Tablets and Minitablets of Deucravacitinib (BMS-986165), and the Effect of Food and pH on the Drug Levels of the Minitablets in Healthy Adults
- First Posted Date
- 2025-02-28
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 26
- Registration Number
- NCT06851871
- Locations
- 🇺🇸
Local Institution - 0001, Austin, Texas, United States
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer
- First Posted Date
- 2025-01-29
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 10
- Registration Number
- NCT06799286
- Locations
- 🇨🇳
Local Institution - 0004, Beijing, Beijing, China
🇨🇳Local Institution - 0003, Jinan, Shandong, China
🇨🇳Local Institution - 0001, Linyi, Shandong, China
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
- Conditions
- Advanced Malignant Tumors
- Interventions
- First Posted Date
- 2025-01-08
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 437
- Registration Number
- NCT06764771
- Locations
- 🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Local Institution - 0020, Allentown, Pennsylvania, United States
🇺🇸The West Clinic, PLLC dba West Cancer Center, Germantown, Tennessee, United States
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2024-12-24
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 42
- Registration Number
- NCT06746402
- Locations
- 🇺🇸
ICON Salt Lake City, Salt Lake City, Utah, United States
🇺🇸Local Institution - 0002, San Antonio, Texas, United States
Clinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Neoadjuvant Nivolumab Plus Chemotherapy in France
- First Posted Date
- 2024-12-16
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 101
- Registration Number
- NCT06735781
- Locations
- 🇫🇷
Centre François Baclesse, Caen, France
🇫🇷Centre Léon Bérard, Lyon, France
🇫🇷Hospices Civils de Lyon, Lyon, France
A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
- First Posted Date
- 2024-12-12
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 360
- Registration Number
- NCT06730750
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸START Midwest, Grand Rapids, Michigan, United States